You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2024

~ Buy the VIVJOA (oteseconazole) Drug Profile, 2024 PDF Report in the Report Store ~

VIVJOA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Vivjoa, and what generic alternatives are available?

Vivjoa is a drug marketed by Mycovia Pharms and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-three patent family members in twenty-two countries.

The generic ingredient in VIVJOA is oteseconazole. One supplier is listed for this compound. Additional details are available on the oteseconazole profile page.

DrugPatentWatch® Generic Entry Outlook for Vivjoa

Vivjoa will be eligible for patent challenges on April 26, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 17, 2036. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VIVJOA?
  • What are the global sales for VIVJOA?
  • What is Average Wholesale Price for VIVJOA?
Summary for VIVJOA
International Patents:63
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 25
Patent Applications: 35
Drug Prices: Drug price information for VIVJOA
What excipients (inactive ingredients) are in VIVJOA?VIVJOA excipients list
DailyMed Link:VIVJOA at DailyMed
Drug patent expirations by year for VIVJOA
Drug Prices for VIVJOA

See drug prices for VIVJOA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VIVJOA
Generic Entry Date for VIVJOA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VIVJOA

VIVJOA is protected by five US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIVJOA is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VIVJOA

Antifungal compounds and processes for making
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Metalloenzyme inhibitor compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: VIVJOA IS INDICATED TO REDUCE THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN FEMALES WITH A HISTORY OF RVVC WHO ARE NOT OF REPRODUCTIVE POTENTIAL

Metalloenzyme inhibitor compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Metalloenzyme inhibitor compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: VIVJOA IS INDICATED TO REDUCE THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN FEMALES WITH A HISTORY OF RVVC WHO ARE NOT OF REPRODUCTIVE POTENTIAL

Antifungal compounds and processes for making
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting VIVJOA

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mycovia Pharms VIVJOA oteseconazole CAPSULE;ORAL 215888-001 Apr 26, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mycovia Pharms VIVJOA oteseconazole CAPSULE;ORAL 215888-001 Apr 26, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mycovia Pharms VIVJOA oteseconazole CAPSULE;ORAL 215888-001 Apr 26, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VIVJOA

When does loss-of-exclusivity occur for VIVJOA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 16233113
Patent: Antifungal compounds and processes for making
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2017018823
Patent: compostos antifúngicos e processos para a fabricação
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 78339
Patent: COMPOSES ANTIFONGIQUES ET PROCEDES DE FABRICATION (ANTIFUNGAL COMPOUNDS AND PROCESSES FOR MAKING)
Estimated Expiration: ⤷  Sign Up

China

Patent: 7428724
Patent: 抗真菌化合物及制备方法 (ANTIFUNGAL COMPOUNDS AND PROCESSES FOR MAKING)
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0221113
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 71347
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 7556
Patent: ПОЛИМОРФНЫЕ ФОРМЫ ПРОТИВОГРИБКОВЫХ СОЕДИНЕНИЙ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ (POLYMORPHIC FORMS OF ANTIFUNGAL COMPOUNDS AND PROCESSES FOR MAKING SAME)
Estimated Expiration: ⤷  Sign Up

Patent: 1792067
Patent: ПРОТИВОГРИБКОВЫЕ СОЕДИНЕНИЯ И СПОСОБЫ ПОЛУЧЕНИЯ
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 71347
Patent: COMPOSÉS ANTIFONGIQUES ET PROCÉDÉS DE FABRICATION (ANTIFUNGAL COMPOUNDS AND PROCESSES FOR MAKING)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 59771
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 71347
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 17012021
Patent: COMPUESTOS ANTIFUNGICOS Y PROCESOS PARA LA FABRICACION. (ANTIFUNGAL COMPOUNDS AND PROCESSES FOR MAKING.)
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 71347
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 71347
Estimated Expiration: ⤷  Sign Up

Serbia

Patent: 566
Patent: ANTIFUNGALNA JEDINJENJA I PROCESI IZRADE (ANTIFUNGAL COMPOUNDS AND PROCESSES FOR MAKING)
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 71347
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2603277
Estimated Expiration: ⤷  Sign Up

Patent: 170129895
Patent: 항진균성 화합물 및 이의 제조 방법
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 26063
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VIVJOA around the world.

Country Patent Number Title Estimated Expiration
Slovenia 2563771 ⤷  Sign Up
South Korea 102603277 ⤷  Sign Up
Canada 2861339 COMPOSES INHIBITEURS DE METALLOENZYMES (METALLOENZYME INHIBITOR COMPOUNDS) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.